NCT02473900View on ClinicalTrials.gov

Evaluating the Bioequivalence of HIP1403, HGP0919

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Healthy
Interventions
DRUG

HIP1403

Oseltamivir 75mg

DRUG

HGP0919

Oseltamivir phosphate 75mg

Trial Locations (1)

Unknown

Korea University Anam Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT02473900 - Evaluating the Bioequivalence of HIP1403, HGP0919 | Biotech Hunter | Biotech Hunter